Diabetes Research and Clinical Practice
Volume 70, Issue 2 , Pages 193-194 , November 2005

Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients

  • Chin-Hsiao Tseng

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan
    • National Taiwan University College of Medicine, Taipei, Taiwan
    • Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 23883578; fax: +886 2 23883578.
    • ,
  • Tien-Shang Huang

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan
    • National Taiwan University College of Medicine, Taipei, Taiwan

References 

  1. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med. 2001;111:10–17
  2. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study, the Pioglitazone 027 Study Group. Clin. Ther. 2000;22:1395–1409
  3. Aronoff S, Rosenblatt S, Braithwaite S, Egan J, Mathisen A, Schneider R the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care. 2000;23:1605–1611
  4. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol. Ther. 2002;4:145–151
  5. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708–711
  6. Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Fogari E, Bertone G, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin. Ther. 2004;26:744–754

PII: S0168-8227(04)00368-7

doi: 10.1016/j.diabres.2004.11.003

Diabetes Research and Clinical Practice
Volume 70, Issue 2 , Pages 193-194 , November 2005

Article Tools